Stock listing
gettex:B1Q NRX Pharmaceuticals, Inc. Aktie
German listing (gettex) of NRX Pharmaceuticals, Inc. · home listing NASDAQ:NRXP
Follow NRX Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:NRXP
$2.15 USD -0.40 (-15.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NRXP
- Day range
- $2.14 – $2.53 USDNov 20, 2026
- Volume
- 1.48M sharesNov 20, 2026
- Market cap
- $95.31M USDAt the close on Nov 20, 2026 · price × 44.33M shares outstanding
- 52-week range
- $1.62 – $5.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.87M USDMedian day 722,101 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NRXP · Home | $2.15 USD | -0.40 (-15.7%) | 1,475,335 | $2.53 | $2.53 | $2.135 | $2.55 | Close on Nov 20, 2026 |
| Frankfurt:B1Q | €2.27 EUR | -0.375 (-14.2%) | 1,000 | €2.23 | €2.27 | €2.23 | €2.645 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NRXP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.15 | -0.40 | -15.7% | $2.53 | $2.53 | $2.135 | 1,475,335 | |
| $2.55 | -0.25 | -8.9% | $2.86 | $2.885 | $2.52 | 1,397,394 | |
| $2.80 | +0.35 | +14.3% | $2.46 | $2.91 | $2.46 | 2,162,095 | |
| $2.45 | +0.30 | +14.0% | $2.145 | $2.47 | $2.09 | 1,598,434 | |
| $2.15 | -0.04 | -1.8% | $2.16 | $2.195 | $2.052 | 728,159 | |
| $2.19 | -0.09 | -3.9% | $2.25 | $2.26 | $2.165 | 1,030,551 | |
| $2.28 | -0.16 | -6.6% | $2.43 | $2.44 | $2.25 | 605,046 | |
| $2.44 | +0.08 | +3.4% | $2.39 | $2.50 | $2.36 | 980,128 | |
| $2.36 | -0.02 | -0.8% | $2.32 | $2.40 | $2.29 | 497,771 | |
| $2.38 | 0.00 | 0.0% | $2.38 | $2.44 | $2.26 | 878,548 | |
| $2.38 | +0.11 | +4.8% | $2.30 | $2.40 | $2.26 | 604,422 | |
| $2.27 | -0.22 | -8.8% | $2.46 | $2.48 | $2.241 | 832,743 | |
| $2.49 | +0.25 | +11.2% | $2.30 | $2.51 | $2.30 | 1,130,890 | |
| $2.24 | +0.07 | +3.2% | $2.165 | $2.34 | $2.11 | 1,799,900 | |
| $2.17 | -0.10 | -4.4% | $2.32 | $2.44 | $2.14 | 2,510,312 | |
| $2.27 | -0.39 | -14.7% | $2.83 | $2.84 | $2.11 | 15,641,670 | |
| $2.66 | -0.03 | -1.1% | $2.70 | $2.773 | $2.615 | 1,760,886 | |
| $2.69 | 0.00 | 0.0% | $2.73 | $2.745 | $2.64 | 834,661 | |
| $2.69 | +0.14 | +5.5% | $2.59 | $2.705 | $2.53 | 749,684 | |
| $2.55 | +0.06 | +2.4% | $2.48 | $2.59 | $2.459 | 594,734 | |
| $2.49 | +0.09 | +3.8% | $2.36 | $2.50 | $2.24 | 840,297 | |
| $2.40 | -0.23 | -8.7% | $2.57 | $2.61 | $2.36 | 1,051,688 | |
| $2.63 | +0.01 | +0.4% | $2.65 | $2.70 | $2.61 | 526,552 | |
| $2.62 | -0.01 | -0.4% | $2.63 | $2.77 | $2.545 | 1,348,553 | |
| $2.63 | +0.03 | +1.2% | $2.815 | $2.815 | $2.623 | 1,093,428 | |
| $2.60 | -0.11 | -4.1% | $2.70 | $2.76 | $2.572 | 1,226,911 | |
| $2.71 | +0.12 | +4.6% | $2.53 | $2.772 | $2.48 | 1,177,679 | |
| $2.59 | -0.11 | -4.1% | $2.64 | $2.705 | $2.56 | 696,336 | |
| $2.70 | -0.15 | -5.3% | $2.85 | $2.85 | $2.675 | 553,869 | |
| $2.85 | 0.00 | 0.0% | $2.85 | $2.93 | $2.815 | 481,039 | |
| $2.85 | -0.04 | -1.4% | $2.89 | $2.89 | $2.82 | 289,405 | |
| $2.89 | -0.01 | -0.3% | $2.88 | $2.895 | $2.805 | 651,765 | |
| $2.90 | -0.04 | -1.4% | $2.88 | $2.93 | $2.87 | 405,069 | |
| $2.94 | +0.07 | +2.4% | $2.89 | $2.975 | $2.825 | 418,910 | |
| $2.87 | -0.035 | -1.2% | $2.91 | $2.93 | $2.785 | 680,823 | |
| $2.905 | +0.055 | +1.9% | $2.91 | $2.94 | $2.82 | 613,067 | |
| $2.85 | -0.07 | -2.4% | $2.94 | $3.00 | $2.833 | 625,975 | |
| $2.92 | 0.00 | 0.0% | $3.035 | $3.06 | $2.91 | 1,172,268 | |
| $2.92 | +0.05 | +1.7% | $2.92 | $2.97 | $2.87 | 515,784 | |
| $2.87 | -0.125 | -4.2% | $2.95 | $3.01 | $2.87 | 736,822 | |
| $2.995 | -0.035 | -1.2% | $3.07 | $3.09 | $2.92 | 793,377 | |
| $3.03 | -0.13 | -4.1% | $3.15 | $3.15 | $3.025 | 681,052 | |
| $3.16 | -0.16 | -4.8% | $3.29 | $3.35 | $3.12 | 552,500 | |
| $3.32 | +0.03 | +0.9% | $3.30 | $3.33 | $3.21 | 495,041 | |
| $3.29 | -0.03 | -0.9% | $3.37 | $3.39 | $3.29 | 380,010 | |
| $3.32 | -0.07 | -2.1% | $3.38 | $3.42 | $3.31 | 947,272 | |
| $3.39 | +0.04 | +1.2% | $3.38 | $3.52 | $3.36 | 789,018 | |
| $3.35 | -0.05 | -1.5% | $3.39 | $3.45 | $3.32 | 716,043 | |
| $3.40 | -0.09 | -2.6% | $3.46 | $3.47 | $3.16 | 1,257,746 | |
| $3.49 | +0.09 | +2.6% | $3.37 | $3.605 | $3.35 | 1,205,425 | |
| $3.40 | 0.00 | 0.0% | $3.44 | $3.44 | $3.37 | 356,231 | |
| $3.40 | +0.03 | +0.9% | $3.36 | $3.45 | $3.32 | 480,116 | |
| $3.37 | -0.10 | -2.9% | $3.48 | $3.52 | $3.34 | 520,713 | |
| $3.47 | -0.02 | -0.6% | $3.50 | $3.54 | $3.42 | 705,974 | |
| $3.49 | +0.06 | +1.7% | $3.43 | $3.50 | $3.39 | 487,720 | |
| $3.43 | -0.03 | -0.9% | $3.48 | $3.50 | $3.425 | 237,362 | |
| $3.46 | +0.02 | +0.6% | $3.46 | $3.50 | $3.38 | 418,341 | |
| $3.44 | -0.04 | -1.1% | $3.45 | $3.51 | $3.42 | 392,760 | |
| $3.48 | -0.07 | -2.0% | $3.52 | $3.545 | $3.43 | 427,013 | |
| $3.55 | -0.07 | -1.9% | $3.63 | $3.68 | $3.50 | 695,596 | |
| $3.62 | +0.16 | +4.6% | $3.51 | $3.62 | $3.47 | 584,036 | |
| $3.46 | -0.21 | -5.7% | $3.62 | $3.62 | $3.38 | 1,011,362 | |
| $3.67 | +0.22 | +6.4% | $3.49 | $3.69 | $3.425 | 895,953 | |
| $3.45 | -0.11 | -3.1% | $3.52 | $3.61 | $3.44 | 898,336 | |
| $3.56 | +0.05 | +1.4% | $3.52 | $3.60 | $3.44 | 615,302 | |
| $3.51 | +0.18 | +5.4% | $3.36 | $3.55 | $3.33 | 811,738 |
Splits
1 split · NASDAQ:NRXP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- gettex:B1Q
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 17, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest earnings call · Nov 17, 2026
NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Sep 14, 2026
Investor Presentation (September 2026)
Investor deck · 20 slides
Latest news
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 17, 2026
Closed $2.45 (+14.0%) on Nov 17, 2026
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
Nov 12, 2026
Closed $2.19 (-3.9%) on Nov 13, 2026
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
Nov 11, 2026
Closed $2.44 (+3.4%) on Nov 11, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
Oct 30, 2026
Closed $2.27 (-14.7%) on Oct 30, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Oct 29, 2026
Closed $2.27 (-14.7%) on Oct 30, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
Oct 19, 2026
Closed $2.63 (+1.2%) on Oct 19, 2026
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
Oct 15, 2026
Closed $2.71 (+4.6%) on Oct 15, 2026
NRx Defense Systems, an NRx Company (Nasdaq: NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
Sep 30, 2026
Closed $2.92 (0.0%) on Sep 30, 2026
NRX Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 51 in the last 12 months · 276 in all · newest Nov 17, 2026 · oldest 2021
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 17, 2026
- Decks
- 10 decks · latest Sep 14, 2026
Where NRX Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NRXP · Home listing | NASDAQ | United States | USD |
| LS Exchange:A4091K | LS Exchange | Germany | EUR |
| Lang & Schwarz:A4091K | Lang & Schwarz | Germany | EUR |
| BOATS:NRXP | BOATS | United States | USD |
| gettex:B1Q · This page | gettex | Germany | EUR |
| Tradegate:B1Q | Tradegate | Germany | EUR |
| Frankfurt:B1Q | Frankfurt | Germany | EUR |
| Hamburg:B1Q | Hamburg | Germany | EUR |
| Munich:B1Q | Munich | Germany | EUR |
Valuation
EV/sales 17.7× against a median of 1.6×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $76.46M USD
- P/E
- Loss
- EV/sales
- 17.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 29.9%
- Operating margin
- −557.1%
- Net margin
- −458.5%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 2.23
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals, Inc. · NASDAQ:NRXP | US$95.31M | US$76.46M | n/a | 17.7× | n/a | n/a | −458.5% | n/a | 2.23 |
| Unicycive Therapeutics, Inc. · NASDAQ:UNCY | US$97.77M | US$39.32M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.09 |
| NovaBridge Biosciences · NASDAQ:NBP | US$96.28M | US$68.30M | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 1.37 |
| Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496 | US$96.17M | US$105.6M | n/a | 7.8× | n/a | n/a | −53.2% | n/a | n/a |
| PDS Biotechnology Corporation · NASDAQ:PDSB | US$95.39M | US$80.15M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | 2.04 |
| Immunic, Inc. · NASDAQ:IMUX | US$95.37M | −US$36.09M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.51 |
| Allergy Therapeutics plc · LSE:AGY | US$95.27M | US$117.1M | n/a | 1.6× | n/a | 17.1× | −72.9% | 6.3× | n/a |
| Voyager Therapeutics, Inc. · NASDAQ:VYGR | US$95.21M | −US$11.60M | n/a | −0.5× | n/a | 0.7× | −416.3% | 0.0× | 1.45 |
| Outlook Therapeutics, Inc. · NASDAQ:OTLK | US$94.94M | US$83.70M | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Molecular Partners AG · SIX:MOLN | US$93.53M | −US$4.92M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Sunhawk Vision Biotech, Inc. · TPEX:7759 | US$93.04M | US$82.43M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| Median of the others | US$95.32M | US$74.22M | 1.6× | 2.5× | −72.9% | 0.0× | 1.41 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.80 · 1 analyst
- Revenue, year to Dec 2026
- 5.61M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jonathan C. Javitt | Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics |
| Michael Abrams | Chief Financial Officer |
| Patrick Flynn | Chief Operating Officer |
| Dennis K. McBride | Chief Strategy Officer |
| Glenn D. Tyson | Chief Commercial Officer |
| Hope Therapeutics | Inc.Chief Business Officer |
| Joshua Brown | Chief Medical Innovation Officer |
| Rick Panicucci | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Jonathan C. Javitt | Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics |
| Brian Korb | Managing Partner, astr partners |
| Chaim Hurvitz | Director |
| Dennis K. McBride | Chief Strategy Officer |
| Patrick Flynn | Chief Operating Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2026 Earnings Call | Tue, Nov 17, 2026 · 8:00 AM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2026 Earnings Call | Mon, Aug 17, 2026 · 4:30 PM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2026 Earnings Call | Mon, May 18, 2026 · 8:00 AM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2025 Earnings Call | Tue, Mar 24, 2026 · 8:00 AM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2025 Earnings Call | Mon, Nov 17, 2025 · 8:30 AM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2025 Earnings Call | Wed, Aug 20, 2025 · 8:00 AM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q1 2025 Earnings Call | Thu, May 15, 2025 · 4:30 PM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q4 2024 Earnings Call | Mon, Mar 17, 2025 · 8:30 AM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q3 2024 Earnings Call | Mon, Nov 18, 2024 · 4:30 PM ET | Replay |
| NRX Pharmaceuticals (NASDAQ:NRXP) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 4:30 PM ET | Replay |
All 22 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | +13.9% |
| Q2 2026 | Aug 14, 2026 · After close | +4.9% |
| Q1 2026 | May 15, 2026 · After close | −5.0% |
| Q4 2025 | Mar 24, 2026 | +36.2% |
| Q3 2025 | Nov 14, 2025 · After close | −15.3% |
| Q2 2025 | Aug 18, 2025 · Before open | −4.5% |
| Q1 2025 | May 15, 2025 | +7.9% |
| Q4 2024 | Mar 14, 2025 · After close | −12.8% |
| Q3 2024 | Nov 14, 2024 · After close | +2.6% |
| Q2 2024 | Aug 14, 2024 · After close | −6.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +1.6% |
| Q4 2023 | Mar 29, 2024 · After close | +11.2% |
| Q3 2023 | Nov 13, 2023 · After close | +4.2% |
| Q2 2023 | Aug 14, 2023 · After close | +2.7% |
| Q1 2023 | May 15, 2023 · After close | −7.3% |
| Q4 2022 | Mar 30, 2023 · After close | −10.6% |
| Q3 2022 | Nov 14, 2022 · After close | +3.6% |
| Q2 2022 | Aug 15, 2022 · After close | +4.5% |
| Q1 2022 | May 16, 2022 · After close | 0.0% |
| Q4 2021 | Mar 31, 2022 · After close | −1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 20 slides | Sep 14, 2026 |
| Investor Presentation (June 2026) | Investor deck | 21 slides | June 2026 |
| Investor Presentation (October 2025) | Investor deck | 25 slides | October 2025 |
| Investor Presentation (December 2024) | Investor deck | 32 slides | December 2024 |
| Investor Presentation (July 2024) | Investor deck | 51 slides | July 2024 |
| Investor Presentation (June 2023) | Investor deck | 34 slides | June 2023 |
| Investor Presentation (September 2022) | Investor deck | 29 slides | September 2022 |
| Investor Presentation (April 2022) | Investor deck | 27 slides | April 2022 |
| Investor Presentation (January 2022) | Investor deck | 45 slides | January 2022 |
| NeuroRx — SPAC Merger (December 2020) | SPAC merger | 25 slides | Dec 17, 2020 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of restricted common stock Closed: US$6.5M raised Buyers: B Group Capital (Led a consortium of biotechnology investors purchasing approximately 3.9 million shares for $6.5 million) Use of proceeds: Capital to reach expected regulatory inflection points | Aug 18, 2025 |
| Debt financing Update: US$7.8M Buyers: Universal Capital, LLC ($7.8 million in debt financing) Use of proceeds: HOPE Therapeutics clinic acquisitions, starting with Dura Medical, Kadima and NeuroSpa clinics | May 28, 2025 |
| Strategic investment of series A Convertible Preferred Stock of HOPE Therapeutics Announced: US$2.5M Use of proceeds: Support the launch of HOPE's clinic network and the closing of its announced clinic acquisitions | Apr 3, 2025 |
| Strategic investment of nRx common stock Cancelled: US$2M · US$2.75 a share · Warrants at US$3 for 24 months Buyers: Smith & Sauer ($2 million in NRx common stock at $2.75 per share); Smith and Sauer ($2.0 million in NRx common stock) Use of proceeds: To advance the new drug applications for NRX-100 and NRX-101 | Mar 17, 2025 |
| Strategic investment of series A Preferred Stock of HOPE Therapeutics Update: US$25M Buyers: Smith & Sauer, LLC ($25 million equity purchases in HOPE Therapeutics Series A Preferred Stock); Smith and Sauer ($25 million in newly issued Series A Preferred Stock of HOPE) Use of proceeds: To fund planned acquisitions of HOPE interventional psychiatry clinics in a nationwide rollup | Jan 28, 2025 |
| Registered direct offering of common stock with common stock purchase warrants Announced: US$3.5M · US$2.88 a share · Warrants at US$2.88 Buyers: Anson Funds Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products | Jan 28, 2025 |
| Senior secured convertible promissory notes Announced: US$5.4M · Warrants at US$3.78 Buyers: Anson Funds Use of proceeds: New Drug Application filings for NRX-100 and NRX-101, launch of HOPE Therapeutics, and potential new pipeline products | Jan 28, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Big Rock Partners Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Nov 20, 2017.
- Price
- US$10.00 a unit
- Units offered
- 6,000,000 units
- Offering size
- US$60 million
- Underwriters' option
- Up to 900,000 more units
- Listing
- BRPAU on the Nasdaq Capital Market
- Underwriters
- EarlyBirdCapital, Inc., I-Bankers Securities, Inc. · In the order on the cover
- Units delivered
- On or about Nov 22, 2017
Steps
| Step | When |
|---|---|
| Filed publicly | Oct 13, 2017 |
| Amended 3 times | Newest Nov 20, 2017 |
| Shares registered with an exchange | Nov 20, 2017 |
| Declared effective by the SEC | Nov 20, 2017 |
| Final prospectus, with the price | Nov 21, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 21, 2017 |
| EFFECT · Notice that a registration is effective | Nov 20, 2017 |
| S-1MEF · Registration of more shares for the same offering | Nov 20, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Nov 20, 2017 |
| S-1/A · Registration statement, amended | Nov 20, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 20, 2017 |
| S-1/A · Registration statement, amended | Nov 17, 2017 |
| CORRESP · Letter to the SEC | Nov 16, 2017 |
| CORRESP · Letter to the SEC | Nov 16, 2017 |
| CORRESP · Letter to the SEC | Nov 16, 2017 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 14, 2017 |
| S-1/A · Registration statement, amended | Nov 14, 2017 |
| UPLOAD · Letter from the SEC | Nov 9, 2017 |
| S-1 · Registration statement | Oct 13, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 21, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.23M | 0 | 0 | 0 | 0 | 0 | ||||
| Cost of revenue | 505.0K | 0 | 5.00K | 4.00K | 2.00K | 2.00K | 1.01M | |||
| Gross profit | 720.0K | -5.00K | -5.00K | -4.00K | -2.00K | -2.00K | -1.01M | |||
| Research and development | 3.78M | 6.20M | 13.4M | 17.0M | 20.3M | 10.6M | 3.50K | |||
| Selling, general and administrative | 13.1M | 13.5M | 14.2M | 27.4M | 74.9M | 11.4M | 2.77K | 1.01M | 134.5K | |
| Operating income | -16.2M | -18.5M | -27.8M | -44.3M | -115.8M | -51.4M | -713.2K | -1.01M | -1.19K | -134.5K |
| Depreciation and amortization | 70.0K | 5.00K | 5.00K | 4.00K | 2.00K | 2.00K | 1 | 1.09M | 52.5K | |
| EBITDA | -16.2M | -18.5M | -27.8M | -44.3M | -115.8M | -51.4M | -713.2K | 82.4K | -82.0K | |
| Interest expense | 671.0K | 230.0K | 120.0K | 4.58M | 18.0K | 56.0K | 0 | 0 | 0 | |
| Income before tax | -28.6M | -25.1M | -30.1M | -39.8M | -93.1M | -51.8M | 492.6K | 82.4K | -1.19K | -105.0K |
| Income tax | 0 | 0 | 0 | -4.58M | -21.3M | 17.8K | 84.2K | 16.3K | 0 | |
| Net income | -28.6M | -25.1M | -30.1M | -39.8M | -93.1M | -51.8M | 408.4K | 66.1K | -1.19K | -105.0K |
| Earnings per share, basic | -1.34 | -2.36 | -3.98 | -0.60 | -1.98 | -1.51 | -0.11 | -0.29 | 0.00 | -0.12 |
| Earnings per share, diluted | -0.60 | -1.98 | -1.51 | -0.11 | -0.29 | 0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.80M | 1.44M | 4.59M | 20.1M | 27.6M | 1.86M | 877.4K | 11.1K | 77.1K | 449.4K |
| Short-term investments | 5.97M | 32.0M | 70.8M | 69.0M | ||||||
| Receivables | 161.0K | 0 | 6.00K | 7.00K | 0 | 831.4K | ||||
| Inventory | -6.00K | -7.00K | 214.0K | |||||||
| Current assets | 8.89M | 3.30M | 6.88M | 25.8M | 32.7M | 2.93M | 69.5K | 30.2K | 123.8K | 536.4K |
| Property, plant and equipment | 63.0K | 10.0K | ||||||||
| Goodwill | 1.79M | 0 | ||||||||
| Total assets | 13.0M | 3.65M | 7.32M | 25.8M | 32.7M | 2.94M | 32.1M | 70.8M | 69.9M | 69.6M |
| Accounts payable | 4.27M | 4.13M | 4.63M | 2.08M | 3.69M | 3.15M | 622.4K | 551.1K | 85.7K | |
| Current liabilities | 28.6M | 21.9M | 19.0M | 15.6M | 11.9M | 46.2M | 622.4K | 567.4K | 375.6K | 93.2K |
| Long-term debt | 5.01M | 2.82M | 2.67M | 1.95M | 690.0K | |||||
| Total debt | 631.0K | 6.58M | 9.16M | 10.5M | 518.0K | 797.0K | 1.95M | 690.0K | ||
| Total liabilities | 28.9M | 26.9M | 19.0M | 18.4M | 11.9M | 46.7M | 2.57M | 1.26M | 93.2K | |
| Shareholders' equity | -15.9M | -23.2M | -11.7M | 7.41M | 20.8M | -43.8M | -4.84M | 5.00M | 5.00M | 69.5M |
| Shares outstanding | 31.7M | 14.6M | 8.39M | 66.4M | 58.8M | 43.0M | 2.84M | 2.73M | 2.64M | 903.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14.1M | -10.6M | -21.7M | -39.8M | -37.7M | -2.27M | -792.7K | -473.2K | -30 | -135.8K |
| Capital spending | 0 | 0 | -3.00K | -10.0K | -7.00K | -2.00K | -1 | 0 | 0 | |
| Free cash flow | -14.1M | -10.6M | -21.7M | -39.8M | -37.7M | -2.27M | -792.7K | -473.2K | -135.8K | |
| Cash from investing | -2.81M | 0 | -3.00K | -10.0K | -7.00K | -2.00K | 40.2M | -647.4K | 0 | -69.0M |
| Cash from financing | 23.3M | 7.49M | 6.20M | 32.2M | 63.5M | 3.25M | -39.5M | 682.5K | 82.5K | 69.6M |
| Share buybacks | -26.3M | -40.7M | 70.0M | |||||||
| Change in cash | 6.35M | -3.15M | -15.5M | -7.55M | 25.7M | 982.0K | -11.1K | -438.3K | 82.5K | 449.4K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 5, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 5, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 2, 2026 | Current report | SEC |
| 8-K · Current report | Oct 16, 2026 | Current report | SEC |
| 8-K · Current report | Oct 5, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 17, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2026 | Current report | SEC |
| 8-K · Current report | Jul 22, 2026 | Current report | SEC |
| 8-K · Current report | Jun 4, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 3, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 25-NSE | May 22, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 24, 2026 | Management or board change | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Feb 24, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Feb 23, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Feb 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 8-K · Current report | Feb 17, 2026 | Current report | SEC |
| 424B5 · Prospectus | Feb 17, 2026 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Feb 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 16, 2026 | Current report | SEC |
| 8-K · Current report | Dec 29, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 23, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 18, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 8-K/A · Current report, amended | Nov 21, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| 8-K · Current report | Sep 12, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 21, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2025 | Results | SEC |
| 424B5 · Prospectus | Aug 18, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 18, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2025 | Current report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2025 | Explanation request | SEC |
| RW · Request to withdraw a registration | Jun 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 24, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jun 20, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| 8-K · Current report | May 21, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| 424B3 · Prospectus | Apr 17, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 21, 2025 | Results | SEC |
| 10-K · Annual report | Mar 14, 2025 | Annual report | SEC |
| D | Mar 7, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 20, 2025 | Offer document | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 29, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Jan 29, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 22, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| S-1 · Registration statement | Nov 14, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 8-K · Current report | Oct 15, 2024 | Material contract | SEC |
| 8-K · Current report | Oct 11, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Sep 5, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 20, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Aug 14, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 8-K · Current report | Aug 14, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 424B3 · Prospectus | Aug 14, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jul 3, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Jun 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Management or board change | SEC |
| 8-K · Current report | May 23, 2024 | Current report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2024 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 19, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Apr 19, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 18, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 15, 2024 | Current report | SEC |
| 424B3 · Prospectus | Apr 15, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Apr 15, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2024 | Results | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Current report | SEC |
| 8-K · Current report | Mar 21, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Mar 20, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Mar 18, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Mar 13, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 8-K · Current report | Feb 28, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Feb 28, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 26, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| 8-K · Current report | Feb 2, 2024 | Current report | SEC |
| 8-K · Current report | Jan 23, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 16, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Dec 29, 2023 | Meeting notice | SEC |
| 8-K · Current report | Dec 29, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 21, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Nov 22, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 22, 2023 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Nov 22, 2023 | Current report | SEC |
| 8-K · Current report | Nov 21, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 19, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 14, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Sep 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 1, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 31, 2023 | Current report | SEC |
| 424B3 · Prospectus | Aug 31, 2023 | Offer document | SEC |
| 4 · Change in ownership | Aug 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Aug 14, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 28, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jun 8, 2023 | Offer document | SEC |
| 8-K/A · Current report, amended | Jun 7, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 6, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 5, 2023 | Material contract | SEC |
| 10-K/A · Annual report, amended | May 26, 2023 | Annual report | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | May 1, 2023 | Annual report | SEC |
| 8-K · Current report | Apr 21, 2023 | Current report | SEC |
| 10-K · Annual report | Mar 31, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2023 | Results | SEC |
| 424B5 · Prospectus | Mar 14, 2023 | Offer document | SEC |
| 8-K/A · Current report, amended | Mar 14, 2023 | Material contract | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 424B5 · Prospectus | Mar 10, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 9, 2023 | Material contract | SEC |
| 8-K · Current report | Mar 3, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Feb 24, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Feb 23, 2023 | Management or board change | SEC |
| 5 · Annual statement of ownership | Feb 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 13, 2023 | Current report | SEC |
| 8-K · Current report | Feb 2, 2023 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jan 10, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 23, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2022 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 19, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2022 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 2, 2022 | Offer document | SEC |
| 4 · Change in ownership | Dec 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 28, 2022 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 23, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 15, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 8-K · Current report | Nov 9, 2022 | Material contract | SEC |
| SC 13D · Big-stake notice | Sep 13, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Aug 22, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 12, 2022 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2022 | Current report | SEC |
This page holds 200 of 480 filings. Open Filings
Cap table
Built by 6ix from NRX Pharmaceuticals, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 44,327,982
- Fully diluted
- 44,327,982
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 44,327,982 | Nov 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 44,327,982 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lori Wittman Other companies: AH Realty Trust, Inc. (Director · Since at least Jun 17, 2026); NetSTREIT Corp. (Director · Since at least Aug 12, 2020); Chiron Real Estate Inc. (Director · Since at least May 30, 2018); Care Capital Properties Inc (EVP and CFO · Jul 31, 2015 – Aug 17, 2017 · Past) | CFO, Director · Nov 20, 2017 – Nov 20, 2017 · Past |
| Michael Abrams Other companies: Arch Therapeutics Inc (CHIEF FINANCIAL OFFICER · May 10, 2021 – Aug 31, 2023 · Past); Silvergraph International Inc (Director · Dec 30, 2011 – Dec 30, 2011 · Past); FitLife Brands, Inc. (CHIEF FINANCIAL OFFICER, Director · Aug 20, 2009 – Dec 31, 2016 · Past) | Chief Financial Officer · Since at least Nov 18, 2024 |
| Seth Van Voorhees Other companies: PDS Biotechnology Corporation (Chief Financial Officer · Jan 1, 2021 – Jun 15, 2021 · Past); Research Frontiers Incorporated (CFO & VP-Business Development · Dec 31, 2017 – Feb 21, 2020 · Past) | CHIEF FINANCIAL OFFICER · Jun 13, 2022 – Dec 16, 2022 · Past |
| Stephen H. Willard Other companies: Longeveron Inc. (Chief Executive Officer · Since at least Feb 11, 2026); E*TRADE Financial LLC (Director · May 10, 2012 – May 9, 2013 · Past) | CHIEF EXECUTIVE OFFICER, Director · Jul 12, 2022 – Dec 16, 2022 · Past |
| Chaim Hurvitz Other companies: Dror Ortho-Design Inc. (Chairman of The Board · Since at least Jun 17, 2024) | Director · Since at least Apr 9, 2025 |
| Herbert Raymond McMaster Other companies: Zoom Communications, Inc. (Director · Since at least May 6, 2020) | Director · May 26, 2021 – Aug 26, 2021 · Past |
| Ira S Strassberg Other companies: Continental Building Products Inc (Director · Mar 10, 2017 – Feb 3, 2020 · Past) | Chief Financial Officer · Mar 15, 2022 – Mar 15, 2022 · Past |
| Richard Clavano Narido Other companies: Lucira Health Inc (Chief Financial Officer · Nov 15, 2022 – Mar 3, 2023 · Past) | Interim CFO · Sep 13, 2023 – Sep 13, 2023 · Past |
| William Fricker Other companies: Immunomedics Inc (Principal Accounting Officer · Aug 23, 2018 – Oct 23, 2020 · Past) | CFO & Treasurer · May 24, 2021 – May 24, 2021 · Past |
| Aaron Gorovitz | Director · May 24, 2021 – Aug 30, 2023 · Past |
All 28 people
| Person | Seat |
|---|---|
| Albert G Rex | Director · Nov 20, 2017 – Nov 20, 2017 · Past |
| Alessandra Daigneault | General Counsel & Secretary · May 24, 2021 – Aug 19, 2021 · Past |
| Brian Korb | Managing Partner, astr partners · Since at least Oct 30, 2026 |
| Daniel Troy | Director · May 24, 2021 – May 24, 2021 · Past |
| Dennis K. McBride | Chief Strategy Officer · Since at least Jun 13, 2024 |
| Glenn D. Tyson | Chief Commercial Officer · Since Apr 13, 2026 |
| Hope Therapeutics | Inc.Chief Business Officer · Since at least Dec 1, 2025 |
| Janet Rehnquist | Director · Dec 28, 2023 – Dec 28, 2023 · Past |
| Jonathan C. Javitt | Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics · Since at least May 24, 2021 |
| Joseph Michael Casper | Chief Operating Officer · Since at least Jan 27, 2026 |
| Joshua Brown | Chief Medical Innovation Officer · Since at least Mar 2, 2026 |
| Patrick Flynn | Chief Operating Officer · Since at least May 24, 2021 |
| Richard Ackerman | President & CEO, Director · May 24, 2021 – May 24, 2021 · Past |
| Richard Birdoff | Director · Nov 20, 2017 – Nov 20, 2017 · Past |
| Rick Panicucci | Chief Technology Officer · Since at least Nov 4, 2026 |
| Robert Besthof | Interim CEO · May 24, 2021 – Mar 8, 2022 · Past |
| Sharon Glied | Director · May 24, 2021 – Oct 21, 2022 · Past |
| Troy T Taylor | Director · Nov 20, 2017 – Nov 20, 2017 · Past |
Log in to ask 6ix AI your own questions about NRX Pharmaceuticals, Inc.